Home > Neurology > AAN 2019 > Multiple Sclerosis and NMOSD > Biotin, ocrelizumab, and ibudilast in progressive MS

Biotin, ocrelizumab, and ibudilast in progressive MS

Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA
AAN 2019
ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3
New real-life data on the use of biotin in progressive MS were presented [1]; there was long-term data of ocrelizumab, the first-ever approved treatment of PPMS, in the open-label extension of the ORATORIO phase 3 trial [2]; in addition, results of a post-hoc analysis of the phase 2 trial SPRINT-MS suggested that the effect of ibudilast on progression of brain atrophy is driven by patients with PPMS, more than SPMS [3]. Biotin High dose biotin has been suggested to improve mitochondrial energy failure and contribute to myelin synthesis. In 5 French MS centres, 579 progressive MS patients were treated with high dose biotin (203 with PPMS and 376 with SPMS) [1]. The mean EDSS at baseline was 6.4; mean duration of biotin therapy was 12.7 years. EDSS improved in 72 patients (12.4%) and worsened in 110 (18.9%). There was no statistically significant difference between SPMS and PPMS patients. The reported EDSS improvement is remarkably similar to that s...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on